BCL2 and small cell lung carcinoma: Interestingly, the sole drug more effective in TTF1-high cell lines was the Bcl2 inhibitor ABT-737, which has been shown to have activity in SCLC PDX models in combination with rapamycin (mTOR inhibitor) [31].